$498 Million is the total value of BVF INC/IL's 29 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 41.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $91,311,000 | +11.2% | 3,255,280 | +17.7% | 18.35% | +18.6% |
| CYTK | Sell | CYTOKINETICS INC | $58,948,000 | +28.5% | 4,851,691 | -2.9% | 11.84% | +37.0% |
| CCXI | Sell | CHEMOCENTRYX INC | $57,709,000 | +18.5% | 7,798,572 | -3.3% | 11.60% | +26.3% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $43,829,000 | +0.5% | 4,986,186 | -22.8% | 8.81% | +7.2% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $26,921,000 | -2.2% | 2,616,249 | -3.9% | 5.41% | +4.3% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $23,437,000 | -6.9% | 3,043,805 | -2.1% | 4.71% | -0.8% |
| FWP | FORWARD PHARMA A/Ssponsored adr | $20,832,000 | -28.5% | 1,387,853 | 0.0% | 4.18% | -23.8% | |
| CTIC | CTI BIOPHARMA CORP | $18,053,000 | +7.7% | 44,796,940 | 0.0% | 3.63% | +14.8% | |
| CLCD | Sell | COLUCID PHARMACEUTICALS INC | $17,630,000 | -39.5% | 484,335 | -36.5% | 3.54% | -35.4% |
| GLYC | Buy | GLYCOMIMETICS INC | $17,240,000 | -0.6% | 2,826,282 | +16.5% | 3.46% | +6.0% |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $13,573,000 | -34.5% | 1,760,489 | -2.8% | 2.73% | -30.1% |
| CASC | New | CASCADIAN THERAPEUTICS INC | $13,504,000 | – | 3,133,224 | +100.0% | 2.71% | – |
| INFI | Buy | INFINITY PHARMACEUTICALS INC | $10,612,000 | +32.1% | 7,860,808 | +52.6% | 2.13% | +40.8% |
| ACHN | New | ACHILLION PHARMACEUTICALS INC COM | $10,008,000 | – | 2,423,300 | +100.0% | 2.01% | – |
| FATE | New | FATE THERAPEUTICS INC | $9,436,000 | – | 3,759,398 | +100.0% | 1.90% | – |
| ARQL | ARQULE INC | $9,324,000 | -29.6% | 7,400,128 | 0.0% | 1.87% | -25.0% | |
| ESPR | Buy | ESPERION THERAPEUTICS INC NE | $8,924,000 | +30.5% | 712,770 | +44.3% | 1.79% | +39.1% |
| ADRO | Buy | ADURO BIOTECH INC | $8,503,000 | +36.5% | 745,886 | +48.8% | 1.71% | +45.5% |
| IMDZ | Buy | IMMUNE DESIGN CORP | $7,261,000 | -20.2% | 1,320,164 | +10.0% | 1.46% | -14.9% |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $6,097,000 | -34.3% | 554,806 | -6.3% | 1.22% | -30.0% |
| GTXI | New | GTX INC DEL | $5,853,000 | – | 1,108,433 | +100.0% | 1.18% | – |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $5,042,000 | +58.0% | 1,392,720 | +90.7% | 1.01% | +68.6% |
| NVLS | Buy | NIVALIS THERAPEUTICS INC | $4,176,000 | -70.0% | 1,864,474 | +9.1% | 0.84% | -68.0% |
| OREXIGEN THERAPEUTICS INCnote 2.750% 20 | $3,000,000 | +13.2% | 10,000,000 | 0.0% | 0.60% | +20.8% | ||
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $2,606,000 | +40.3% | 1,854,768 | +82.4% | 0.52% | +49.7% |
| PTIE | PAIN THERAPEUTICS INC | $1,299,000 | -43.0% | 2,278,552 | 0.0% | 0.26% | -39.2% | |
| OREXQ | OREXIGEN THERAPEUTICS INC | $1,279,000 | -47.6% | 734,976 | 0.0% | 0.26% | -44.1% | |
| XOMA | New | XOMA CORP DEL | $1,278,000 | – | 302,800 | +100.0% | 0.26% | – |
| ANTH | New | ANTHERA PHARMACEUTICALS INC | $40,000 | – | 62,292 | +100.0% | 0.01% | – |
| GBIM | Exit | GLOBEIMMUNE INC | $0 | – | -657,653 | -100.0% | -0.16% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -865,773 | -100.0% | -0.20% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -375,000 | -100.0% | -1.49% | – |
| GTXI | Exit | GTX INC DEL | $0 | – | -11,512,000 | -100.0% | -1.70% | – |
| TBRA | Exit | TOBIRA THERAPEUTICS INC | $0 | – | -399,433 | -100.0% | -2.99% | – |
| CASC | Exit | CASCADIAN THERAPEUTICS INC | $0 | – | -18,799,368 | -100.0% | -5.81% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.